KYMR•benzinga•May 22, 2024 at 03:27 PM

Kymera Therapeutics To Present New Preclinical Data For KT-621, An Oral STAT6 Degrader At The ATS Annual Meeting; KT-621 Expected To Start Phase 1 In The Second Half Of 2024, With Phase 1 Data In The First Half Of 2025

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 22, 2024 by benzinga